Regeneron Pharmaceuticals (REGN) Other Operating Expenses (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Other Operating Expenses of $703.5 million for Q2 2026, down 8.79% quarter-over-quarter from $771.3 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Other Operating Expenses (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Other Operating Expenses history runs 18 years deep, the most recent figure standing at $703.5 million for Q2 2026.
- In Q2 2026, Other Operating Expenses changed N/A year-over-year to $703.5 million; the TTM figure through Jun 2026 stood at $1.5 billion (up 6418.3% YoY), while the FY2025 annual figure was $10.0 million, up 118.73% from the prior year.
- Other Operating Expenses for Q2 2026 stood at $703.5 million, down from $771.3 million in the prior quarter.
- The five-year high for Other Operating Expenses was $771.3 million in Q1 2026, with the low at -$15.5 million in Q4 2024.
- The 5-year median for Other Operating Expenses is $600000.0 (2023), against an average of $101.6 million.
- The sharpest annual moves came in 2024 and 2025: Other Operating Expenses slumped 3200.0% in 2024, then soared 225.0% in 2025.
- Regeneron Pharmaceuticals' Other Operating Expenses stood at $6.6 million in 2022, then sank by 92.42% to $500000.0 in 2023, then plunged by 3200.0% to -$15.5 million in 2024, then surged by 164.52% to $10.0 million in 2025, then soared by 6935.0% to $703.5 million in 2026.
- Business Quant data shows REGN's Other Operating Expenses at $703.5 million in Q2 2026, $771.3 million in Q1 2026, and $10.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 703.50 Mn |
| Mar 31, 2026 | 771.30 Mn |
| Sep 30, 2025 | 10.00 Mn |
| Dec 31, 2024 | -15.50 Mn |
| Sep 30, 2024 | -8.00 Mn |
| Jun 30, 2024 | -14.60 Mn |
| Mar 31, 2024 | -15.30 Mn |
| Dec 31, 2023 | 500,000.00 |
| Sep 30, 2023 | 500,000.00 |
| Jun 30, 2023 | 600,000.00 |
| Mar 31, 2023 | 500,000.00 |
| Dec 31, 2022 | 6.60 Mn |
| Sep 30, 2022 | 45.70 Mn |
| Jun 30, 2022 | 17.40 Mn |
| Mar 31, 2022 | 20.20 Mn |
| Dec 31, 2021 | 15.80 Mn |
| Sep 30, 2021 | -42.00 Mn |
| Jun 30, 2021 | 31.30 Mn |
| Mar 31, 2021 | 40.50 Mn |
| Dec 31, 2020 | 145.20 Mn |